A Study on the Dosage of Bupivacaine for Spinal Block in Cesarean Section for Parturients at Plains and Sub-Plateau Regions

A Study on the Dosage of Bupivacaine for Spinal Block in Cesarean Section at Sub-Plateau Regions

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400088600

Enrollment

Unknown

Registered

2024-08-22

Start date

2024-09-30

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Plain group/ Sub-plateau group:Randomly assigned patients to receive one of seven doses of bupivacaine (intrathecal hyperbaric bupivacaine at 6.75, 7.5, 8.25, 9, 9.75, 10.5, and 11.25 mg) using random

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Parturients aged 20-40 years with a body mass index of 18-28 kg/m^2 who have been living locally and are scheduled for elective cesarean section.

Exclusion criteria

Exclusion criteria: ASA (American Society of Anesthesiologists) physical status classification > II, gestational age < 37 weeks, pregnancy-related complications requiring clinical intervention, fetal or placental abnormalities such as premature rupture of membranes, intrauterine growth restriction, etc., and contraindications to intraspinal anesthesia.

Design outcomes

Primary

Measure	Time frame
ED90 of bupivacaine;	—

Secondary

Measure	Time frame
Incidence of adverse reactions;	—

Countries

China

Contacts

Public Contactyang chen

Obstetrics and Gynecology Hospital of Fudan University

annie.114@163.com+86 56319779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026